目的 探讨曲美布汀联合奥替溴铵治疗肠易激综合征的临床效果。方法 选取2016年8月-2017年8月在通城县人民医院治疗的肠易激综合征患者76例，随机分为对照组（36例）和治疗组（40例）。对照组口服奥替溴铵片，80 mg/次，2次/d。治疗组在对照组基础上餐前30 min口服马来酸曲美布汀片，200 mg/次，3次/d。两组患者均持续治疗4周。观察两组患者临床疗效，比较治疗前后两组患者临床症状改善时间及P物质（SP）、生长抑素（SS）和神经肽Y（NPY）水平。结果 治疗后，对照组和治疗组的临床总有效率分别为77.78%、95.00%，两组比较差异具有统计学意义（P<0.05）。治疗后，治疗组腹部不适、大便性状与次数改善的时间均显著短于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者SP、SS水平较治疗前显著下降，NPY水平显著升高，同组比较差异具有统计学意义（P<0.05）；且治疗组SP、SS和NPY水平显著优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 曲美布汀联合奥替溴铵治疗肠易激综合征疗效显著，安全性好，具有一定的临床推广应用价值。

Objective To discuss the clinical effect of trimebutine combined otilonium bromide in treatment of irritable bowel syndrome. Methods Patients (76 cases) with irritable bowel syndrome in Tongcheng Hospital from August 2016 to August 2017 were randomly divided into control (36 cases) and treatment (40 cases) groups. Patients in the control group were po administered with Otilonium Bromide Tablets, 80 mg/time, twice daily. Patients in the treatment group were po administered with Trimebutine Maleate Tablets on the basis of the control group 30 min before the meal, 200 mg/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the improvement time of clinical symptom, as well as SP, SS and NPY levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 77.78% and 95.00%, respectively, and there were differences between two groups (P < 0.05). After treatment, the improvement time of abdominal discomfort, stool characters and times in the treatment group was significantly shorter than that in the control group, with significant difference between two groups (P < 0.05). After treatment, the SP and SS levels in two groups were significantly decreased, but NPY level was significantly increased, and there were differences in the same group (P < 0.05). And the SP, SS and NPY levels in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Trimebutine combined otilonium bromide has significant curative effect in treatment of irritable bowel syndrome with high safety, which has a certain clinical application value.